Plasma Brain Natriuretic Peptide as a Noninvasive Marker for Efficacy of Pulmonary Thromboendarterectomy
|
|
- Valentine Rich
- 5 years ago
- Views:
Transcription
1 Plasma Brain Natriuretic Peptide as a Noninvasive Marker for Efficacy of Pulmonary Thromboendarterectomy Noritoshi Nagaya, MD, Motomi Ando, MD, Hideo Oya, MD, Yutaka Ohkita, MD, Shingo Kyotani, MD, Fumio Sakamaki, MD, and Norifumi Nakanishi, MD Departments of Internal Medicine and Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan Background. Plasma brain natriuretic peptide (BNP), a cardiac hormone secreted mainly by the cardiac ventricles, has been shown to increase in proportion to the degree of cardiac overload. However, whether plasma BNP may serve as a marker for the efficacy of pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension remains unknown. Methods. Plasma BNP level was measured in 34 patients with chronic thromboembolic pulmonary hypertension before and 1 month after pulmonary thromboendarterectomy. Right heart catheterization was also performed before and 1 month after the operation. Results. Preoperative plasma BNP level was significantly elevated in patients with chronic thromboembolic pulmonary hypertension compared with control patients ( vs 13 2 pg/ml; p < 0.001; n 34) and was positively correlated with total pulmonary resistance (r 0.57; p < 0.001). After pulmonary thromboendarterectomy, plasma BNP level in survivors markedly decreased ( to 54 9 pg/ml; p < 0.001; n 32) in association with a reduction of total pulmonary resistance ( to Wood units; p < 0.001). The change in plasma BNP level was closely correlated with that in total pulmonary resistance (r 0.63; p < 0.001). Importantly, a sustained elevation of plasma BNP (> 50 pg/ml) indicated the presence of residual pulmonary hypertension (> 5 Wood units) after operation (sensitivity 73%; specificity 81%). Conclusions. Plasma BNP level was strongly associated with the severity of pulmonary hypertension in patients with chronic thromboembolic pulmonary hypertension and thereby may serve as a noninvasive marker for the efficacy of pulmonary thromboendarterectomy. (Ann Thorac Surg 2002;74:180 4) 2002 by The Society of Thoracic Surgeons Chronic thromboembolic pulmonary hypertension (CTEPH) is the result of chronic obstruction of the pulmonary arteries by thrombi [1]. These obstructed pulmonary arteries contribute to the development of pulmonary hypertension, which ultimately leads to right heart failure and death. Earlier studies have shown that pulmonary thromboendarterectomy strikingly decreases pulmonary vascular resistance and improves survival in patients with major-vessel CTEPH [2 4]. Nevertheless, operative mortality rates are relatively high, and inadequate hemodynamic improvement is observed in some patients with CTEPH [3 5]. Thus noninvasive assessment of the efficacy of pulmonary thromboendarterectomy would be desirable in the management of CTEPH patients after operation. Plasma brain natriuretic peptide (BNP), a cardiac hormone secreted mainly by the cardiac ventricles [6, 7], has been used as a noninvasive marker of left ventricular dysfunction and a prognostic indicator in a variety of Accepted for publication March 30, Address reprint requests to Dr Nagaya, Department of Internal Medicine, National Cardiovascular Center, Fujishirodai, Suita, Osaka , Japan; nagayann@hsp.ncvc.go.jp. patients with left-sided heart failure [8, 9]. Recently we have shown that plasma BNP level increases in proportion to the degree of pulmonary hypertension and right ventricular dysfunction [10, 11]. However, whether plasma BNP may serve as a marker for the efficacy of pulmonary thromboendarterectomy in patients with CTEPH remains unknown. Thus in the present study, we measured plasma BNP levels before and 1 month after pulmonary thromboendarterectomy. The purposes of this study were investigate the following: (1) whether preoperative plasma BNP level is elevated in relation to disease severity in patients with CTEPH, (2) whether plasma BNP level decreases in association with hemodynamic improvement after pulmonary thromboendarterectomy, and (3) whether postoperative plasma BNP level can identify residual pulmonary hypertension after operation, thereby serving as a potential marker for the efficacy of thromboendarterectomy in patients with CTEPH. Material and Methods Study Patients This study included 34 patients with CTEPH (13 men and 21 women; mean age, 49 years; age range, 22 to 64 years) who underwent pulmonary thromboendarterectomy 2002 by The Society of Thoracic Surgeons /02/$22.00 Published by Elsevier Science Inc PII S (02)
2 Ann Thorac Surg NAGAYA ET AL 2002;74:180 4 PLASMA BNP AND PULMONARY THROMBOENDARTERECTOMY 181 from January 1996 to October The preoperative condition was New York Heart Association functional class III (n 27) or IV (n 7). The diagnosis of CTEPH was made on the basis of the previously reported procedure [12]. In brief, patients with clinical symptoms suggesting CTEPH underwent ventilation and perfusion lung scanning to detect pulmonary perfusion defects. The diagnosis was confirmed by pulmonary angiography. All patients had occlusion and stenosis from the lobar to segmental arteries [13]. Cardiac catheterization was performed to confirm pre-capillary pulmonary hypertension (mean pulmonary arterial pressure 30 mm Hg with pulmonary capillary wedge pressure 12 mm Hg). All patients received anticoagulation therapy before and after pulmonary thromboendarterectomy. Vasodilators such as prostacyclin or its analogue and calcium antagonists were used in 22 patients. Medications were not significantly changed before and after operation, except vasodilators, which were discontinued because of significant improvement in pulmonary hypertension. The study included 12 age-matched control patients (5 men and 7 women; mean age, 50; age range, 29 to 67 years). All patients gave written informed consent. Hemodynamic Studies Right heart catheterization was performed in all 34 patients before pulmonary thromboendarterectomy. In addition, catheterization was repeated in 32 patients 1 month after operation because of 2 operative deaths. Hemodynamic variables including mean pulmonary arterial pressure, mean right atrial pressure, and mean pulmonary wedge pressure were measured. Cardiac output was determined by Fick s method [14]. Total pulmonary resistance was calculated by dividing mean pulmonary arterial pressure by cardiac output. Right ventricular and left ventricular ejection fraction at base line was determined in 30 patients using electron-beam computed tomography, as reported previously [10]. Blood Sampling and Assay Blood samples for base line measurements were drawn from a peripheral vein in all 34 patients at diagnostic catheterization when the patient was in a stable hemodynamic state. Blood sampling was repeated in 32 patients 1 month after pulmonary thromboendarterectomy. Blood was immediately transferred into a chilled glass tube containing disodium ethylenediaminete-traacetic acid (1 mg/ml) and aprotinin (500 U/mL) and centrifuged immediately at 4 C, and then the plasma was frozen and stored at 80 C until assay. Plasma BNP level was measured directly with a specific immunoradiometric assay kit (Shiono RIA BNP Assay Kit; Shionogi Co, Ltd, Osaka, Japan) [8]. Pulmonary Thromboendarterectomy Pulmonary thromboendarterectomy was performed through two separate arteriotomies on both main intrapericardial pulmonary arteries following the standard technique described previously [3, 15]. Table 1. Clinical and Hemodynamic Parameters Before and After Pulmonary Thromboendarterectomy Before After p Value a New York Heart Association functional class No. of deaths NA 2 NA Hemodynamics Heart rate, bpm NS Mean systemic arterial NS pressure (mm Hg) Mean pulmonary artery pressure (mm Hg) Cardiac output (L/min) Total pulmonary resistance (Wood units) Pulmonary capillary NS wedge pressure (mm Hg) Mean right arterial pressure (mm Hg) Gas exchange SaO 2 (%) SvO 2 (%) Medication use Anticoagulant agents NS Digitalis NS Diuretics NS Prostacyclin or its analogue Calcium antagonists 4 2 NS a p 0.05 versus before operation. NA not applicable; NS not significant; SaO 2 arterial oxygen pressure; SvO 2 mixed venous oxygen saturation. Statistical Analysis All data were expressed as mean value standard error of the mean. Log transformation was used to normalize the distribution of plasma BNP level unless otherwise indicated. Comparisons of measurements between two groups were made by unpaired Student s t test. Comparisons of measurements among three groups were made by one-way analysis of variance, followed by the Scheffe s multiple comparison test. Changes in clinical and hemodynamic measurements by thromboendarterectomy were compared by paired Student s t test (Table 1). Correlation coefficients between hemodynamic measurements and plasma BNP level were determined by linear regression analysis. A p value less than 0.05 was considered statistically significant. Results Elevation of Preoperative Plasma BNP Level in Patients With CTEPH Preoperative plasma BNP level was significantly elevated in patients with CTEPH compared with control patients
3 182 NAGAYA ET AL Ann Thorac Surg PLASMA BNP AND PULMONARY THROMBOENDARTERECTOMY 2002;74:180 4 Fig 1. Preoperative plasma brain natriuretic peptide (BNP) level in patients with chronic thromboembolic pulmonary hypertension according to New York Heart Association (NYHA) functional classes. *p less than 0.05 versus controls; p less than 0.05 versus NYHA functional class III. Fig 3. Change in plasma brain natriuretic peptide (BNP) level by pulmonary thromboendarterectomy. (Post postoperative; Pre preoperative.) Fig 2. Relationship between preoperative plasma brain natriuretic peptide (BNP) level and total pulmonary resistance in patients with chronic thromboembolic pulmonary hypertension. ( vs 13 2 pg/ml, p 0.001). Plasma BNP level increased significantly with the severity of New York Heart Association functional class (Fig 1). Preoperative pulmonary arterial pressure (r 0.37; p 0.05) and negatively with cardiac output (r 0.57; p 0.001), thus showing a strong positive correlation with total pulmonary resistance (r 0.57; p 0.001) (Fig 2). Preoperative right atrial pressure (r 0.40; p 0.05) but not with pulmonary capillary wedge pressure (r 0.28; p NS). Preoperative right ventricular ejection fraction was markedly decreased (30% 2%), whereas left ventricular ejection fraction was preserved (63% 2%). Plasma BNP level was inversely correlated with right ventricular ejection fraction (r 0.53; p 0.01), although it was not significantly correlated with left ventricular ejection fraction (r 0.21; p not significant). Reduction of Plasma BNP Level After Pulmonary Thromboendarterectomy Pulmonary thromboendarterectomy markedly decreased total pulmonary resistance in patients with CTEPH ( to Wood units, p 0.001). Plasma BNP level also markedly decreased after operation ( to 54 9 pg/ml; p 0.001) (Fig 3). The decrease in plasma BNP level was closely correlated with the decrease in total pulmonary resistance after thromboendarterectomy (r 0.63, p 0.001) (Fig 4). Postoperative pulmonary arterial pressure (r 0.33, p 0.05), total pulmonary resistance (r 0.45, p 0.01), and mean right atrial pressure (r 0.43, p 0.01), although it was not significantly correlated with cardiac output (r 0.27; p not significant) or pulmonary capillary wedge pressure (r 0.26, p not significant). Interestingly, 1 patient had an increase in his levels between preoperative and postoperative examination. He had severe pericardial effusion and high right atrial pressure (14 mm Hg) after operation.
4 Ann Thorac Surg NAGAYA ET AL 2002;74:180 4 PLASMA BNP AND PULMONARY THROMBOENDARTERECTOMY 183 Fig 4. Relationship between change in plasma brain natriuretic peptide (BNP) level and change in total pulmonary resistance by pulmonary thromboendarterectomy. Sustained Elevation of Plasma BNP Level in Patients With Residual Pulmonary Hypertension After One month after pulmonary thromboendarterectomy, residual pulmonary hypertension ( 5 Wood units) was observed in 11 patients with CTEPH. Postoperative plasma BNP level was significantly higher in these patients with residual pulmonary hypertension than in those without (92 20 vs 32 4 pg/ml; p 0.001). Interestingly, a sustained elevation of plasma BNP ( 50 pg/ml) indicated the presence of residual pulmonary hypertension with sensitivity of 73% and specificity of 81%. Comment In the present study, we demonstrated that (1) preoperative plasma BNP level increased with disease severity of CTEPH, (2) plasma BNP level decreased in association with a reduction of total pulmonary resistance by pulmonary thromboendarterectomy, and (3) a sustained elevation of postoperative BNP level indicated the presence of residual pulmonary hypertension after operation. Pulmonary thromboendarterectomy has been shown to improve hemodynamic status and survival in patients with CTEPH [2 4]. However, this procedure does not always result in normalized pulmonary vascular resistance, most likely caused by superimposed peripheral thromboembolic disease. Inadequate reduction of pulmonary vascular resistance may limit the quality of life and prognosis of patients after operation. Thus it is important to assess the degree of hemodynamic improvement by pulmonary thromboendarterectomy in patients with CTEPH. In the present study, preoperative plasma BNP level was markedly elevated in patients with CTEPH (19 times the controls). In addition, plasma BNP level was positively correlated with total pulmonary resistance. These results suggest that plasma BNP level reflects the disease severity in patients with CTEPH. Considering that BNP is secreted predominantly from the cardiac ventricles through a constitutive pathway in association with the degree of myocardial stretch, damage, and ischemia [6, 7, 16], increased secretion of BNP may be attributable to right ventricular overload caused by pulmonary hypertension. To investigate whether plasma BNP level can be used as a noninvasive marker for the efficacy of thromboendarterectomy, we measured preoperative and postoperative BNP levels in patients with CTEPH. Expectedly, successful pulmonary thromboendarterectomy markedly decreased total pulmonary resistance. Plasma BNP level also decreased 1 month after operation. Furthermore, the decrease in plasma BNP level was closely correlated with the reduction of total pulmonary resistance by pulmonary thromboendarterectomy. It is possible that a decrease in pulmonary vascular resistance may attenuate increased wall stress in the right ventricle, resulting in the reduction of BNP secretion in patients with CTEPH. Thus plasma BNP may serve as a noninvasive marker for the efficacy of pulmonary thromboendarterectomy. Residual pulmonary hypertension is one of the most important risk factors for death in patients with CTEPH. In the present study, a sustained elevation of plasma BNP level was observed in 10 patients with residual pulmonary hypertension after operation. Interestingly, a sustained elevation of plasma BNP ( 50 pg/ml) indicated the presence of residual pulmonary hypertension ( 5 Wood units) with high sensitivity and specificity. These results suggest that postoperative plasma BNP level may be helpful to detect inadequate hemodynamic improvement after operation. Measurement of plasma BNP is simple, noninvasive, and relatively inexpensive. Preoperative plasma BNP level may be a marker for disease severity in patients with CTEPH. The difference between preoperative and postoperative BNP levels may reflect improvement in pulmonary hemodynamics. A second measurement of plasma BNP level may identify residual pulmonary hypertension. Thus repeated measurements of plasma BNP level may complement invasive hemodynamic markers in evaluation of the efficacy of pulmonary thromboendarterectomy in patients with CTEPH. In conclusion, plasma BNP level was strongly associated with the severity of pulmonary hypertension in patients with CTEPH and thereby may serve as a noninvasive marker for the efficacy of pulmonary thromboendarterectomy. This work was supported in part by the research grant for cardiovascular disease (12C-2) from the Ministry of Health, Labor and Welfare, Osaka, Japan, the Uehara Memorial Foundation, Tokyo, Japan, and a grant from the Japan Cardiovascular Research Foundation, Osaka, Japan.
5 184 NAGAYA ET AL Ann Thorac Surg PLASMA BNP AND PULMONARY THROMBOENDARTERECTOMY 2002;74:180 4 References 1. Benotti JR, Dalen JE. The natural history of pulmonary embolism. Clin Chest Med 1984;5: Moser KM, Auger WR, Fedullo PF. Chronic major vessel thrombo-embolic pulmonary hypertension. Circulation 1990;81: Jamieson SW, Auger WR, Fedullo PF, et al. Experienced results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993; 106: Archibald CJ, Auger WR, Fedullo RN, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999;160: Tscholl D, Langer F, Wendler O, et al. Pulmonary thromboendarterectomy risk factors for early survival, and hemodynamic improvement. Eur J Cardiothorac Surg 2001;19: Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332: Mukoyama M, Nakao K, Saito Y, et al. Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, ANP and BNP. J Clin Invest 1991;87: Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90: Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96: Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31: Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102: Viner SM, Bagg BR, Auger WR, Ford GT. The management of pulmonary hypertension secondary to chronic thromboembolic disease. Prog Cardiovasc Dis 1994;37: Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. Radiology 1992;182: Antman EM, Marsh JD, Green LH, Grossman W. Blood oxygen measurements in the assessment of intracardiac left to right shunts: a critical appraisal of methodology. Am J Cardiol 1980;46: Ando M, Takamoto S, Okita Y, et al. for chronic pulmonary thromboembolism accompanied by thrombophilia in 8 patients. Ann Thorac Surg 1998;66: Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995; 92: INVITED COMMENTARY Pulmonary thromboendarterectomy has been shown to be a very effective treatment option for patients with thromboembolic pulmonary hypertension. It drastically reduces pulmonary vascular resistance and markedly improves right ventricular function and exercise ability. Despite increasing experience, a number of questions remain in conjunction with this operation. Patient selection for this treatment as opposed to lung transplantation still involves subjective decision criteria. The early postoperative course is characterized by marked hemodynamic instability and increased vasopressor support, indicating the action of systemic factors such as cytokines that in this disease appear to have a more pronounced effect than in other areas of cardiac surgery. The exact pathomechanism still needs to be elucidated. While PTE has obvious advantages over lung transplantation, only limited long-term data have been published after surgical desobliteration of the pulmonary arterial tree. The information that is available is mostly limited to survival and NYHA stage which are very crude parameters. In the process of generating hemodynamic follow-up data, we have in some patients found a marked discrepancy between persistent pulmonary hypertension and their (subjective) NYHA class. Thus, more objective (and possibly non-invasive parameters) are needed. The current investigation by Nagaya and coworkers is one step in this direction. It still leaves a number of questions. In view of the correlation between BNP and pulmonary artery pressure and resistance, could it be used as a prognostic indicator in preoperative decisionmaking? What are the reasons for the limited sensitivity and specificity of BNP as a predictor for persistent PHT? How marked would the effect of concomitant left heart failure be? Much more information will be needed until we understand the physiology of the disease better, which will hopefully aid us in choosing our treatment options better and refine them further. Hans-Joachim Schäfers, MD Department of Thoracic and Cardiovascular Surgery University of Saarland Kirrberger Str. Homburg/Saar D-66421, Germany 2002 by The Society of Thoracic Surgeons /02/$22.00 Published by Elsevier Science Inc PII S (02)
Influence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion
Influence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion Keizo Kazuhiko TSUCHIDA,MD TANABE, MD Abstract Objectives. Plasma brain natriuretic peptide BNP concentration is
More informationM ost patients with primary pulmonary hypertension or
3 CARDIOVASCULAR MEDICINE Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension N Nagaya, Y Shimizu, T Satoh, H Oya,
More informationAnn Vasc Dis Vol. 6, No. 3; 2013; pp Online August 12, Annals of Vascular Diseases doi: /avd.oa Original Article
Ann Vasc Dis Vol. 6, No. 3; 2013; pp 578 582 Online August 12, 2013 2013 Annals of Vascular Diseases doi:10.3400/avd.oa.13-00056 Original Article Respiratory and Hemodynamic Changes in Patients with Chronic
More informationReal life management of CTEPH: patient case
2 nd International Congress on cardiovascular imaging in clinical practice k Real life management of CTEPH: patient case Anastasia Anthi Pulmonary Hypertension Clinic, Attikon University Hospital, Athens
More informationORIGINAL ARTICLE. Editorial p 320. Methods. Pulmonary Circulation. 476 YAMAKI S et al.
476 YAMAKI S et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Pulmonary Circulation Histopathological Examination by Lung Biopsy
More informationPulmonary Hypertension Surgical Options. Primary pulmonary hypertension. Transplantation. Thromboembolic disease Endarterectomy
Stuart W. Jamieson Cardiothoracic Surgery University of California San Diego Chronic Thromboembolic Pulmonary Hypertension Pulmonary Hypertension Surgical Options Primary pulmonary hypertension Transplantation
More informationComparison with plasma angiotensin II and endothelin-1
European Heart Journal (1999) 2, 1799 187 Article No. euhj.1999.1746, available online at http://www.idealibrary.com on Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationLong-Term Recovery of Exercise Ability After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension
Long-Term Recovery of Exercise Ability After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension Hitoshi Matsuda, MD, Hitoshi Ogino, MD, Kenji Minatoya, MD, Hiroaki Sasaki, MD, Norifumi
More informationArne K. Andreassen, PhD a, *, Ragnhild Wergeland, MS b, Svein Simonsen, PhD a, Odd Geiran, PhD c, Cecilia Guevara, BSc a, and Thor Ueland, PhD d
N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Disease Severity in a Heterogeneous Group of Patients With Chronic Precapillary Pulmonary Hypertension Arne K. Andreassen, PhD a, *, Ragnhild
More informationΚαθετηριασμός δεξιάς κοιλίας. Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ
Καθετηριασμός δεξιάς κοιλίας Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ The increasing interest in pulmonary arterial hypertension (PAH), the increasing interest in implantation of LVADs, and the evolution
More informationHemodynamic Monitoring
Perform Procedure And Interpret Results Hemodynamic Monitoring Tracheal Tube Cuff Pressure Dean R. Hess PhD RRT FAARC Hemodynamic Monitoring Cardiac Rate and Rhythm Arterial Blood Pressure Central Venous
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationVascular Medicine. Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy
Vascular Medicine Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy Kurt W. Jensen, MD; Kim M. Kerr, MD; Peter F. Fedullo, MD;
More informationDetectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension
Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension Adam Torbicki, MD; Marcin Kurzyna, MD; Paweł Kuca, MD; Anna Fijałkowska,
More informationA-type (atrial) and B-type (brain) natriuretic peptides (ANP and
Secretion of A-type and B-type natriuretic peptides into the bloodstream and pericardial space in children with congenital heart disease Yoshio Ootaki, MD, PhD Masahiro Yamaguchi, MD, PhD Naoki Yoshimura,
More informationΕπεμβατικές στρατηγικές στην πνευμονική υπέρταση
Επεμβατικές στρατηγικές στην πνευμονική υπέρταση Παναγιώτης Καρυοφύλλης Καρδιολόγος Ωνάσειο Καρδιοχειρουργικό Κέντρο Mortality in PAH 2015 ESC/ERS Guidelines. Treatment algorithm Since BAS is performed
More informationCTEPH. surgical treatment. Ph. Dartevelle, E. Fadel, S. Mussot, D. Fabre, O. Mercier and G. Simonneau PARIS-SUD UNIVERSITY
CTEPH surgical treatment Ph. Dartevelle, E. Fadel, S. Mussot, D. Fabre, O. Mercier and G. Simonneau MARIE-LANNELONGUE HOSPITAL BICETRE HOSPITAL PARIS-SUD UNIVERSITY Clinical Classification of PH G Simonneau
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationW e1 CARDIOVASCULAR MEDICINE
573 CARDIOVASCULAR MEDICINE Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationCardiovascular Images
Cardiovascular Images Pulmonary Embolism Diagnosed From Right Heart Changes Seen After Exercise Stress Echocardiography Brian C. Case, MD; Micheas Zemedkun, MD; Amarin Sangkharat, MD; Allen J. Taylor,
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationThe Final 10-Year Follow-up Results from the Bari Randomized Trial J Am Coll Cardiol (2007) 49;1600-6
The Final 10-Year Follow-up Results from the Bari Randomized Trial J Am Coll Cardiol (2007) 49;1600-6 n&list_uids=17433949 64-Multislice Detector Computed Tomography Coronary Angiography as Potential Alternative
More informationThe efficacy of pulmonary thromboendarterectomy on long-term gas exchange
Eur Respir J 1997; 10: 2066 2072 DOI: 10.1183/09031936.97.10092066 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 The efficacy of pulmonary
More informationLung cancer is generally a disease of older adults, and
B-Type Natriuretic Peptide as a Predictor of Postoperative Cardiopulmonary in Elderly Patients Undergoing Pulmonary Resection for Lung Cancer Takashi Nojiri, MD, Masayoshi Inoue, MD, PhD, Kazuhiro Yamamoto,
More informationA 50-Year-Old Woman With Dyspnea, Lower Extremity Edema, and Volume Loss of the Right Hemithorax. Eugene Shostak, MD; and Akmal Sarwar, MD, FCCP
CHEST A 50-Year-Old Woman With Dyspnea, Lower Extremity Edema, and Volume Loss of the Right Hemithorax Eugene Shostak, MD; and Akmal Sarwar, MD, FCCP Postgraduate Education Corner PULMONARY AND CRITICAL
More informationEffects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation
J Cardiol 2001 ; 37: 27 33 Effects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation 1 2 1 Masato Kouki KISHIDA, MD WATANABE, MD Abstract Objectives. Cilostazol, an antithrombotic agent,
More informationHemodynamic, Renal, and Hormonal Effects of Adrenomedullin Infusion in Patients With Congestive Heart Failure
Hemodynamic, Renal, and Hormonal Effects of Adrenomedullin Infusion in Patients With Congestive Heart Failure Noritoshi Nagaya, MD; Toru Satoh, MD; Toshio Nishikimi, MD; Masaaki Uematsu, MD; Shinichi Furuichi,
More informationMedical Therapy for Chronic Thromboembolic Pulmonary Hypertension
Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension Josanna Rodriguez-Lopez, MD Pulmonary Hypertension and Thromboendarterectomy Program Massachusetts General Hospital Harvard Medical School
More information2
1 2 Although the term "cardiomyopathy" could theoretically apply to almost any disease affecting the heart, it is usually reserved for "severe myocardial disease leading to heart failure".cardiomyopathy
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationCHAPTER X - SECONDARY PULMONARY HYPERTENSION CHRONIC PULMONARY THROMBOEMBOLISM (HTP). PULMONARY THROMBENDARTERECTOMY
CHAPTER X - SECONDARY PULMONARY HYPERTENSION CHRONIC PULMONARY THROMBOEMBOLISM (HTP). PULMONARY THROMBENDARTERECTOMY Walter KLEPETKO, PhD, VIENNA - AUSTRIA Marian GASPAR, PhD, TIMISOARA 10. 1. Definition.
More informationAustralian Journal of Basic and Applied Sciences, 9(36) December 2015, Pages: ISSN: Journal home page:
ISSN:1991-8178 Australian Journal of Basic and Applied Sciences Journal home page: www.ajbasweb.com Role of Biochemical Tests Artery Disease (ANP, BNP) in the Evaluation of Patients with Coronary 1 Saad
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationWhat is. InSpectra StO 2?
What is InSpectra StO 2? www.htibiomeasurement.com What is InSpectra StO 2? Hemoglobin O 2 saturation is measured in three areas: 1) Arterial (SaO 2, SpO 2 ) Assesses how well oxygen is loading onto hemoglobin
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload Cardiac output (CO) represents the volume of blood that is delivered
More informationNothing to Disclose. Severe Pulmonary Hypertension
Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis
More informationDISTAL PULMONARY THROMBOENDARTERECTOMY: IS IT WORTH IT?
DISTAL PULMONARY THROMBOENDARTERECTOMY: IS IT WORTH IT? Bob Moraca, MD Associate Professor of Surgery Surgical Director of The CTEPH Program Director of Thoracic Aortic and Arrhythmia Surgery Allegheny
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationWHY ADMINISTER CARDIOTONIC AGENTS?
Cardiac Pharmacology: Ideas For Advancing Your Clinical Practice The image cannot be displayed. Your computer may not have enough memory to open the image, or Roberta L. Hines, M.D. Nicholas M. Greene
More informationPulmonary Endarterectomy Improves Dyspnea by the Relief of Dead Space Ventilation
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationUniversity of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem
University of Groningen BNP and NT-proBNP in heart failure Hogenhuis, Jochem IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationTopics to be Covered. Cardiac Measurements. Distribution of Blood Volume. Distribution of Pulmonary Ventilation & Blood Flow
Topics to be Covered MODULE F HEMODYNAMIC MONITORING Cardiac Output Determinants of Stroke Volume Hemodynamic Measurements Pulmonary Artery Catheterization Control of Blood Pressure Heart Failure Cardiac
More informationDr. Rami M. Adil Al-Hayali Assistant Professor in Medicine
Dr. Rami M. Adil Al-Hayali Assistant Professor in Medicine Venous thromboembolism: pulmonary embolism (PE) deep vein thrombosis (DVT) 1% of all patients admitted to hospital 5% of in-hospital mortality
More informationPulmonary thromboendarterectomy (PTE) is indicated for
Pulmonary Thromboendarterectomy Steven R. Meyer, MD, PhD, and Christopher G.A. McGregor, MB, FRCS, MD (Hons) Division of Cardiovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota.
More informationCor pulmonale. Dr hamid reza javadi
1 Cor pulmonale Dr hamid reza javadi 2 Definition Cor pulmonale ;pulmonary heart disease; is defined as dilation and hypertrophy of the right ventricle (RV) in response to diseases of the pulmonary vasculature
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationBio-Molecular Markers for Cardiovascular Disease: Significance of Natriuretic Peptides and Adrenomedullin
REVIEW Korean Circ J 2008;38:507-513 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2008 The Korean Society of Cardiology Bio-Molecular Markers for Cardiovascular Disease: Significance of Natriuretic
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,
More informationBrief View of Calculation and Measurement of Cardiac Hemodynamics
Cronicon OPEN ACCESS EC CARDIOLOGY Review Article Brief View of Calculation and Measurement of Cardiac Hemodynamics Samah Alasrawi* Pediatric Cardiologist, Al Jalila Children Heart Center, Dubai, UAE *
More informationChronic Thromboembolic Pulmonary Hypertension (CTEPH): A Primer
Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Primer H. Page McAdams, MD Duke University Medical Center Durham, NC 27710 page.mcadams@duke.edu Question Which of the following imaging tests is
More informationListing Form: Heart or Cardiovascular Impairments. Medical Provider:
Listing Form: Heart or Cardiovascular Impairments Medical Provider: Printed Name Signature Patient Name: Patient DOB: Patient SS#: Date: Dear Provider: Please indicate whether your patient s condition
More informationSerum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension*
CHEST Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* Anna Fijalkowska, MD; Marcin Kurzyna, MD; Adam Torbicki, MD; Grzegorz Szewczyk, MD; Michał
More informationPatricia A. Thistlethwaite, MD, PhD, Aaron Kemp, BA, Lingling Du, MD, Michael M. Madani, MD, and Stuart W. Jamieson, MB, FRCS
Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension Patricia A. Thistlethwaite, MD, PhD, Aaron Kemp, BA, Lingling Du, MD, Michael M. Madani, MD, and Stuart
More informationScreening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels
Screening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels Toru SUZUKI, MD, Kazuhide YAMAOKI,MD,OsamuNAKAJIMA, 1 MD, Tsutomu YAMAZAKI, MD, Yoshiharu YAMADA,
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationDifferent Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure
464 Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure Michihiro Yoshimura, MD; Hirofumi Yasue, MD; Ken Okumura, MD; Hisao
More informationHemodynamic Monitoring and Circulatory Assist Devices
Hemodynamic Monitoring and Circulatory Assist Devices Speaker: Jana Ogden Learning Unit 2: Hemodynamic Monitoring and Circulatory Assist Devices Hemodynamic monitoring refers to the measurement of pressure,
More informationHaemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome
Heart ;:53 5 53 Department of Internal Medicine, National Cardiovascular Centre, 5-7-1 Fujishirodai, Suita, Osaka 55-55, Japan HOya N Nagaya T Satoh F Sakamaki S Kyotani N Nakanishi K Miyatake College
More informationTHE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU
THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU Cardiology Dept. Rambam Health Care Campus Rappaport Faculty of Medicine Technion, Israel Why the Right Ventricle? Pulmonary hypertension (PH) Right
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationManagement of a Patient after the Bidirectional Glenn
Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe
More informationRelationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction
European Heart Journal (2003) 24, 346 355 Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction T. Tsutamoto
More informationRapid Publication. Cardiac Secretion of Adrenomedullin in Human Heart Failure. Abstract. Methods. Introduction
Rapid Publication Cardiac Secretion of Adrenomedullin in Human Heart Failure Michihisa Jougasaki, Richard J. Rodeheffer, Margaret M. Redfield, Kazuhiro Yamamoto, Chi-Ming Wei, Linda J. McKinley, and John
More informationPulmonary Endarterectomy: Assessment of Operability, Surgical Description, and Post-op Care
Pulmonary Endarterectomy: Assessment of Operability, Surgical Description, and Post-op Care David Poch, MD Division of Pulmonary and Critical Care University of California San Diego La Jolla, CA Victor
More informationin Patients Having Aortic Valve Replacement John T. Santinga, M.D., Marvin M. Kirsh, M.D., Jairus D. Flora, Jr., Ph.D., and James F. Brymer, M.D.
Factors Relating to Late Sudden Death in Patients Having Aortic Valve Replacement John T. Santinga, M.D., Marvin M. Kirsh, M.D., Jairus D. Flora, Jr., Ph.D., and James F. Brymer, M.D. ABSTRACT The preoperative
More informationPeripartum Cardiomyopathy. Lavanya Rai Manipal
Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting
More informationLocal Coverage Determination (LCD) for Cardiac Catheterization (L29090)
Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationGlenn and Fontan Caths:
Glenn and Fontan Caths: Pre-operative evaluation and Trouble-shooting Cavo-Pulmonary Shunts Daniel H. Gruenstein, M.D. Director, Pediatric Interventional Cardiology University of Minnesota Children s Hospital,
More informationPulmonary Hypertension: Definition and Unmet Needs
Heart Failure Center Hadassah University Hospital Pulmonary Hypertension: Definition and Unmet Needs Israel Gotsman The Heart Failure Center Hadassah University Hospital I DO NOT have a financial interest/
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationThe Treatment Targets in Acute Decompensated Heart Failure
SUCCESS WITH HEART FAILURE The Treatment Targets in Acute Decompensated Heart Failure Gregg C. Fonarow, MD The Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los
More informationThe management of chronic thromboembolic pulmonary
Technique of Pulmonary Thromboendarterectomy Isabelle Opitz, MD, and Marc de Perrot, MD, MSc, FRCSC Toronto Pulmonary Endarterectomy Program, Toronto General Hospital, Ontario, Canada. Address reprint
More informationADVANCED CARDIOVASCULAR IMAGING. Medical Knowledge. Goals and Objectives PF EF MF LF Aspirational
Medical Knowledge Goals and Objectives PF EF MF LF Aspirational Know the basic principles of magnetic resonance imaging (MRI) including the role of the magnetic fields and gradient coil systems, generation
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationDr. J. R. Rawal 1 ; Dr. H. S. Joshi 2 ; Dr. B. H. Roy 3 ; Dr. R. V. Ainchwar 3 ; Dr. S. S. Sahoo 3 ; Dr. A. P. Rawal 4 ; Dr. R. A.
(6) EFFECT OF ORAL SILDENAFIL ON RESIDUAL PULMONARY ARTERIAL HYPERTENSION IN PATIENTS FOLLOWING SUCCESSFUL PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY (PBMV): SHORT TERM RESULTS IN 12 PATIENTS. Dr. J. R.
More informationMechanical Ventilation & Cardiopulmonary Interactions: Clinical Application in Non- Conventional Circulations. Eric M. Graham, MD
Mechanical Ventilation & Cardiopulmonary Interactions: Clinical Application in Non- Conventional Circulations Eric M. Graham, MD Background Heart & lungs work to meet oxygen demands Imbalance between supply
More informationPatient referral for elective coronary angiography: challenging the current strategy
Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology
More informationPulmonary Hypertension: Follow-up in adolescence and adults
Pulmonary Hypertension: Follow-up in adolescence and adults Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center University of Muenster Germany
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationPulmonary Thromboembolectomy in Congenital Antithrombin III Deficiency Associated with Acute Pulmonary Embolism Report of a Case
Case Report Pulmonary Thromboembolectomy in Congenital Antithrombin III Deficiency Associated with Acute Pulmonary Embolism Report of a Case Junichiro Takahashi, MD, 1 Masamichi Ito, MD, 1 Jun Okude, MD,
More informationPlasma Atrial and Brain Natriuretic Peptide Levels in Dogs with Congestive Heart Failure
Plasma Atrial and Brain Natriuretic Peptide Levels in Dogs with Congestive Heart Failure Kazushi ASANO, Keiko MASUDA, Masahiro OKUMURA, Tsuyoshi KADOSAWA and Toru FUJINAGA Laboratory of Veterinary Surgery,
More informationRight Heart Catheterization. Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich
Right Heart Catheterization Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich Right Heart Catheterization Pressure measurements Oxygen saturation measurements Cardiac output, Vascular
More informationImpedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency
Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency Aim of haemodynamic monitoring in ICU and ED Detection and therapy of insufficient organ perfusion Answers to common cardiovascular
More informationManagement of Heart Failure in Adult with Congenital Heart Disease
Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationGeorgios C. Bompotis Cardiologist, Director of Cardiological Department, Papageorgiou Hospital,
Georgios C. Bompotis Cardiologist, Director of Cardiological Department, Papageorgiou Hospital, Disclosure Statement of Financial Interest I, Georgios Bompotis DO NOT have a financial interest/arrangement
More informationWhat is controversial in diagnostic imaging?
Controversies in the management of pulmonary hypertension What is controversial in diagnostic imaging? G. Derumeaux Lyon University Hospices Civils de Lyon France Déclaration de Relations Professionnelles
More informationORIGINAL ARTICLE. Abstract. Introduction. Materials and Methods
ORIGINAL ARTICLE Effects of Cardiac Hemodynamics on Agreement in the ph, HCO3- and Lactate Levels between Arterial and Venous Blood Samples in Patients with Known or Suspected Chronic Heart Failure Satoshi
More informationCoagulation-Fibrinolysis System and Postoperative Outcomes of Patients With Chronic Thromboembolic Pulmonary Hypertension
970 KATO F et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Pulmonary Circulation Coagulation-Fibrinolysis System and Postoperative
More information